SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies around the project, calling for a pump and highlighting its potential as the first ETF on Solana. Increased volume and accumulation are fueling optimism, though some caution against potential scams. Discussions also involve related meme coins like UPDOG and FARTCOIN.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is gaining traction as a community-driven meme coin, with many highlighting its solid community and potential for growth. Conversations revolve around its strong connection to internet culture and references to trending on UpDog. Investors are expressing bullish sentiment, anticipating further upward momentum.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community anticipates potential gains, drawing attention to its connection with AI and autonomous agent technology. Grok's (Elon Musk AI) recommendations have fueled speculation about substantial returns, with community members actively discussing potential catalysts and real-world applications. The broader narrative focuses on Fetch.ai's role in the AI and crypto space, with some suggesting it's undervalued despite recent market fluctuations.

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is trending as community members highlight positive sentiment and strong buying activity. Conversations suggest a potential breakout, with many urging others to buy before a significant price increase. Some users are also discussing the coin's activity and tracking via Phantom wallet.

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

Mamo is trending as the community discusses its potential following a significant price run and subsequent pullback, with attention focused on the anticipated launch of The Base App in Q4. Some community members are speculating on price targets and the potential for substantial user growth once the app is released, while others express concerns about recent price action.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets (SSB.X) is trending as the community discusses potential gains from tokens $PUPU.X, $FIRECOIN.X, $PHUM.X, $FIRECOIN.X, and $AINAL.X within its ecosystem. Community members highlight bullish charts and the potential for significant growth, with some drawing comparisons to past meme coin successes like PEPE.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL.X) is trending amid community discussions about its trading volume and potential connections to other cryptocurrencies. Some traders are suggesting short positions based on technical analysis, while others express concerns about the project's activity and tokenomics, with comparisons being drawn to other stablecoins and yield protocols. The community is also actively speculating about price targets and the potential impact of new exchange listings.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

$RENDER.X is trending as users discuss its potential in the AI sector and speculate on possible catalysts. Some community members mention its connection to Grok AI and potential for significant gains, while others analyze its price action and discuss accumulation strategies. Conversations also address the token's migration to Solana and upcoming events like Rendercon.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to a mix of factors, including a recent FDA roadblock for Spinraza and ongoing discussions around its Alzheimer's drug, Leqembi. The community is actively discussing potential growth opportunities, pipeline developments, and analyst ratings, while some express frustration over the stock's performance and perceived lack of movement despite positive news.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Recent buzz around $NU centers on its upcoming earnings report, with analysts highlighting potential for growth driven by its expanding customer base and operations in Latin America, plus expansion news in Argentina. Community members are actively debating the stock's valuation relative to peers like $SOFI and its potential for long-term growth, while weighing the impact of macroeconomic factors and political developments in Brazil. Discussions also focus on the company's executive leadership and adoption of technological innovations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?

CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Gains 35% in 3 Months: How Should You Play the Stock?

MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mirumpharma.com/news-events/News/news-details/2025/Mirums-LIVMARLI-Now-FDA-Approved-in-Tablet-Formulation/default.aspx">announced</a> that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of its drug Livmarli for the treatment of cholestatic pruritus in patients with certain liver diseases.Livmarli is an orally administered ileal bile acid transporter inhibitor. It is used to treat cholestatic pruritus or intense itching caused by impaired bile flow in patients with rare liver diseases called Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).Mirum President Peter Radovich said that the approval for Livmarli in tablet form provides a “meaningful additional treatment option” for patients with ALGS and PFIC.He said that while younger patients can use liquid dosing, older patients can use a one-tablet-per-dose option. He added that the company has had “tremendous success” with Livmarli since launch.In 2024, Livmarli's net product <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mirumpharma.com/news-events/News/news-details/2025/Mirum-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Business-Update/default.aspx">sales</a> totaled $213.3 million, accounting for a whopping 63% of the company’s total net product sales.The tablets are expected to be available in June through Mirum Access Plus pharmacy.On Stocktwits, retail sentiment around Mirum Pharmaceuticals jumped further into the ‘bullish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:649/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_2_10_41_PM_png_a632468a1b.webp" alt="MIRM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 14, 2025 | Source: Stocktwits" width="649" height="149"><figcaption>MIRM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the shares have been forming a “good base” since last year and stand the potential of touching $60.<stembedurl>https://stocktwits.com/buddyopalosam/message/611569108</stembedurl><a href="https://stocktwits.com/symbol/MIRM">MIRM stock</a> is down by over 6% year-to-date but has gained over 64% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cara-therapeutics-announces-1-for-3-reverse-stock-split/chfCXBzRbaQ">Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Equity

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

MIRM
Mirum Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MIRM News

MIRM Mirum Pharmaceuticals Inc